<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661440</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 92579-0707/1</org_study_id>
    <secondary_id>EudraCT Number 2007-002595-34</secondary_id>
    <nct_id>NCT00661440</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus</brief_title>
  <official_title>Efficacy and Safety of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus: a Randomized, Double-blind, Placebo-controlled, Single Center, Proof of Concept Study Using a Two-period Cross-over Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in
      the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition,
      a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be
      included; this subgroup will be analyzed in an exploratory manner only.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Screening, Baseline, Week 3, 7, 11, 14, 18, and Follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>nystagmus intensity, expanded nystagmus acuity function, reading ability, questionnaires, safety parameter</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Nystagmus, Congenital Idiopathic</condition>
  <condition>Nystagmus, Acquired</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neramexane mesylate</intervention_name>
    <description>2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>- verum, placebo</other_name>
    <other_name>- placebo, verum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with congenital idiopathic nystagmus or acquired nystagmus subsequent to
             multiple sclerosis

          -  male or female outpatients

          -  aged between 18 and 80 years (inclusive) at screening

        Exclusion Criteria:

          -  patients with evidence of neurologic disorders other than CIN such as congenital
             nystagmus due to albinism or retinal diseases and/or acquired nystagmus (exemption:
             secondary to MS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Gottlob, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leicester, Leicester, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Leicester, Leicester Royal Infirmary, Ophthalmology Group</name>
      <address>
        <city>Leicester</city>
        <zip>LE2 7LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <last_update_submitted>November 25, 2009</last_update_submitted>
  <last_update_submitted_qc>November 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nystagmus, Pathologic</mesh_term>
    <mesh_term>Nystagmus, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

